Digoxin Can Be Continued in Acute Heart Failure, But With Important Caveats
Yes, you can keep digoxin in acute heart failure, particularly if the patient has concurrent atrial fibrillation with rapid ventricular rate or is already on chronic digoxin therapy, but exercise caution and monitor closely for toxicity. The decision depends critically on the clinical context, underlying rhythm, and specific patient characteristics.
Clinical Decision Algorithm
If Patient Has Atrial Fibrillation with Rapid Rate:
- Continue or initiate digoxin for rate control, especially in decompensated heart failure patients prior to beta-blocker initiation 1, 2, 1
- Digoxin is useful for initial ventricular rate control in rapid AF (Class I recommendation, Level C evidence) 1, 2
- Target resting heart rate <80 bpm, exercise heart rate 110-120 bpm 1
If Patient Has Sinus Rhythm:
- Continue digoxin if already on chronic therapy (Class IIa recommendation, Level B evidence) 1
- Digoxin may be considered in decompensated HF patients, though beta-blockers are preferred long-term 2, 1
- For patients with LVEF <40% and persistent symptoms despite GDMT, digoxin reduces hospitalizations but does not affect mortality 3, 4
Critical Safety Considerations in Acute HF
High-Risk Situations - Exercise Extreme Caution:
Acute myocardial infarction: Digoxin is NOT recommended as it may increase myocardial oxygen demand and lead to ischemia 5
Electrolyte disturbances: The acute HF setting frequently involves:
- Hypokalemia (from aggressive diuresis)
- Hypomagnesemia
- Hypercalcemia All predispose to digoxin toxicity even at therapeutic levels 1, 5
Renal dysfunction: Common in acute HF and dramatically increases toxicity risk. Recent data shows eGFR <60 mL/min is an independent risk factor for toxic digoxin levels (HR 5.27) 6
Mandatory Monitoring in Acute HF:
- Check baseline digoxin level if patient already on therapy
- Monitor electrolytes closely - particularly potassium, magnesium, calcium
- Assess renal function - adjust dose for eGFR <60 mL/min
- Target therapeutic range: 0.6-1.2 ng/mL (lower than historically recommended) 2
- Watch for toxicity signs: cardiac arrhythmias, nausea, visual changes, confusion 5
Specific Dosing Guidance for Acute HF
If continuing chronic digoxin:
- Verify appropriateness of current dose
- Reduce dose in elderly (>70 years), renal impairment, low body weight
- Use 0.125 mg daily or 0.0625 mg daily in high-risk patients 2, 1
If initiating digoxin:
- Loading doses generally NOT required in stable acute HF 2, 1
- Start with maintenance dose: 0.25 mg daily (normal renal function) or 0.125 mg daily (elderly/renal impairment)
- For IV administration: 50-100 mcg IV equivalent to 62.5-125 mcg oral 5
Important Nuances from Recent Evidence
A 2025 multicenter study found that digoxin initiation after acute HF was associated with certain patient characteristics (AF, female sex, reduced LVEF) but had no effect on 90-day outcomes overall 7. However, there was an interaction suggesting potential harm in patients with chronic kidney disease.
Another 2023 Chinese study of IV digoxin 0.5 mg daily in acute HFrEF found that 50% of patients reached toxic levels and 30% experienced toxicity, particularly those with eGFR <60 mL/min, higher normalized doses, and ischemic cardiomyopathy 6. This underscores that fixed dosing is inappropriate in acute HF.
Contraindications - Do NOT Use Digoxin:
- Wolff-Parkinson-White syndrome with AF - risk of ventricular fibrillation 5
- Second- or third-degree heart block without pacemaker 1, 2, 1
- Pre-excitation syndromes 1, 2
- Myocarditis (may precipitate vasoconstriction) 5
- HFpEF (LVEF >40%) in sinus rhythm - may decrease cardiac output 5
Key Pitfalls to Avoid
Don't assume chronic digoxin is appropriate: A 2023 Spanish study found 42% of patients with acute HF were on "inadequate" chronic digoxin therapy, though this didn't impact short-term outcomes 8
Don't use high doses: The 0.5 mg daily dose commonly used is too high for many patients in acute HF, particularly with renal dysfunction 6
Don't forget drug interactions: Amiodarone, diltiazem, verapamil, certain antibiotics, and quinidine increase digoxin levels 2
Don't overlook cardioversion planning: Consider reducing or holding digoxin 1-2 days before electrical cardioversion to avoid ventricular arrhythmias 5
Bottom Line Recommendation
Continue digoxin in acute HF if the patient has AF with inadequate rate control or is already on appropriate chronic therapy for HFrEF with LVEF <40%. However, immediately verify the dose is appropriate for current renal function, check electrolytes and digoxin level, and monitor closely for toxicity. In patients with acute MI, severe renal dysfunction (eGFR <30 mL/min), or significant electrolyte abnormalities, strongly consider holding digoxin until stabilized. The therapeutic window is narrow in acute HF, and the risk-benefit ratio shifts unfavorably in many acute settings 5, 6.